[1]Kimelberg HK. Water homeostasis in the brain: basic concepts[J]. Neuroscience, 2004, 129(4):851-860.
[2]Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema[J]. Pediatr Nephrol, 2007, 22(6):778-784.
[3]Zhao M, Yang H, Jiang X,et al. Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic stem cells[J]. Mol Biotechnol, 2008, 40(1):19-26.
[4]McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue[J]. J Cell Biol, 1980, 85(3):890-902.
[5]Shi ZhF, Han M, Xu LX, et al. A scratch-wound model in cultured rat astrocytes[J]. Chinese Journal of Rehabilitation Theory and Practice, 2007, 13(12):1132-1133.(in Chinese)师忠芳,韩明,徐立新,等. 体外培养大鼠星形胶质细胞划伤模型[J]. 中国康复理论与实践,2007,13(12):1132-1133.
[6]Qi LL, Fang SH, Shi WZ, et al. CysLT2 receptor-mediated AQP4 up-regulation is involved in ischemic-like injury through activation of ERK and p38 MAPK in rat astrocytes[J]. Life Sci, 2011, 88(1-2):50-56.
[7]Zhang J, Hua ZC. Targeted gene silencing by small interfering RNA-based knock-down technology[J]. Curr Pharm Biotechnol, 2004, 5(1):1-7.
[8]Cuccato G, Polynikis A, Siciliano V, et al. Modeling RNA interference in mammalian cells[J]. BMC Syst Biol, 2011, 5:19-30.
[9]Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vector-mediated gene delivery[J]. Biotechnol J, 2009, 4(11):1559-1572.
[10]Zhang S, Zhi D, Huang L. Lipid-based vectors for siRNA delivery[J]. J Drug Target, 2012, 20(9):724-735.
[11]Kamaci N, Emnacar T, Karakas N, et al. Selective silencing of DNA topoisomerase IIβ in human mesenchymal stem cells by siRNAs (small interfering RNAs)[J]. Cell Biol Int Rep, 2011, 18(1):e00010.
[12]Nabzdyk CS, Chun M, Pradhan L, et al. High throughput RNAi assay optimization using adherent cell cytometry[J]. J Transl Med, 2011, 9:48-56. |